With the innovation in space of technology and growth in the demand for pharmaceutical products across the globe to decrease the burden of diseases, healthcare system is rapidly progressing. As a result of this market trend, the overall landscape for contract development and manufacturing organisation (CDMO) is evolving to meet growing expectations of the customer. A change in landscape can be observed in drug development with the growth in space of complex formulations. Large Pharmaceutical companies are striving to de-risk their R&D efforts and increase the speed to market of their pipeline drugs, while simultaneously reducing their development and manufacturing costs. A growing number of specialty and biotech firms rely on service providers (CDMOs) to avoid the high fixed costs of in-house development, manufacturing capabilities and expertise required to drive their molecules through clinical development. With the advancement of services such as Antibody Conjugation Services (ADC) and High Potency Manufacturing, the demand for CDMOs has increased, as these services require large investment to have the capabilities in-house. CDMOs are consolidating to become integrated service providers by expanding their offerings and building their organization’s capacity through varied smaller transactions. Consider, a drug manufacturing CDMO acquires a drug development plant. Now it can provide services for Drug Manufacturing and drug Development. Engagement with an Integrated CDMO is growing as companies prefer strategic partnerships as well as the ability to engage with a limited number of suppliers for their outsourcing needs. The ability of CDMOs to take up projects and seamlessly Integrate the development and manufacturing of API and Formulation is highly sought-after. CDMOs can deal with drug candidates with high complexities, offer access their specialized expertise and ease the pressure of capital investments require for the development and manufacturing of drugs Additionally, integration of project present the advantage of having one point-of-contact overseeing the entire length of project. This decreases the hassle for the pharma companies to coordinate it at multiple ends. In brief, the trend to avail the benefits of integrated services offered by CDMOs is rapidly growing ensuring the products are brought to the market more efficiently, safely and cost-effectively
0 Comments
Leave a Reply. |
|